【复星医药(02196.HK)：盐酸左沙丁胺醇雾化吸入溶液获注册批准】智通财经APP讯，复星医药(02196.HK)发布公告，近日，公司控股子公司复星医药(徐州)有限公司关于盐酸左沙丁胺醇雾化吸入溶液(以下简称“该药品”)的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于治疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.